Virax Biolabs Group Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year Ending	TTM	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	-6.92	-5.46	-1.71	-0.65	-0.71
Share-Based Compensation	1.59	1.75	0.29	0	0
Other Operating Activities	-0.01	-0.48	0.61	0.06	-0.03
Operating Cash Flow	-5.34	-4.18	-0.81	-0.59	-0.74
Capital Expenditures	-0.71	-0.18	0	0	0
Investing Cash Flow	-0.71	-0.18	0	0	0
Share Issuance / Repurchase	7.1	13.65	0.52	0.4	0
Debt Issued / Paid	-0.42	0.03	0.29	0.18	0.7
Other Financing Activities	0.09	-	-	-	-
Financing Cash Flow	6.77	13.69	0.81	0.59	0.7
Net Cash Flow	0.54	9.33	0	-0	-0.04
Free Cash Flow	-6.05	-4.36	-0.81	-0.59	-0.74
Free Cash Flow Margin	-7628.04%	-50907.25%	-	-476.65%	-745.54%
Free Cash Flow Per Share	-3.41	-4.10	-0.85	-2.45	-7.13

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).